Propanc Biopharma (PPCB) Enterprise Value Growth (1y) (2016 - 2025)
Propanc Biopharma (PPCB) Enterprise Value Growth (1y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -6,403.42% |
| Jun 30, 2025 | 42.67% |
| Mar 31, 2025 | -715.81% |
| Dec 31, 2024 | 79.58% |
| Sep 30, 2024 | -39.89% |
| Jun 30, 2024 | -109.86% |
| Mar 31, 2024 | 93.33% |
| Dec 31, 2023 | -192.74% |
| Sep 30, 2023 | 65.84% |
| Jun 30, 2023 | -147.04% |
| Dec 31, 2022 | 66.75% |
| Sep 30, 2022 | 57.67% |
| Jun 30, 2022 | -80.35% |
| Dec 31, 2021 | -246.54% |
| Mar 31, 2021 | 46.44% |
| Dec 31, 2020 | -76.70% |
| Mar 31, 2020 | 74.86% |
| Dec 31, 2019 | 90.35% |
| Sep 30, 2019 | -147.01% |
| Jun 30, 2019 | 87.98% |